Prader-Willi syndrome
MONDO:0008300Prader-Willi syndrome is a rare genetic disorder characterized by hypothalamic-pituitary abnormalities with severe hypotonia during the neonatal period and first two years of life and the onset of hyperphagia with a risk of morbid obesity during infancy and adulthood, learning difficulties and behavioral problems or severe psychiatric problems.
Also known as: Prader-Labhart-Willi syndrome, Prader-Willi syndrome, Prader-Willi-Labhart syndrome, Willi-Prader syndrome, PWS, Prader-Willi syndrome chromosome region, Prader-Willi-like syndrome associated with chromosome 6, obesity, muscular hypotonia, intellectual disability, short stature, hypogonadotropic hypogonadism, and small hands and feet
32 clinical trials for this condition and its sub-types, 31 tagged with Prader-Willi syndrome itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Prader-Willi syndrome
-
Schaaf-Yang syndrome 0 trials
-
New nasal spray aims to curb relentless hunger in rare genetic disorder
Disease control Stopped earlyThis study tests the long-term safety of a nasal spray called carbetocin for people with Prader-Willi syndrome who experience severe, constant hunger (hyperphagia). About 160 participants who completed a previous study will receive the spray three times daily. The goal is to see …
Phase 3 • Sponsor: ACADIA Pharmaceuticals Inc. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New hope for rare hunger disorder: drug shows promise in Long-Term trial
Disease control Stopped earlyThis study tests whether ARD-101 can safely reduce extreme hunger and food-related behaviors in people with Prader-Willi syndrome over 12 months. About 90 participants who completed a prior study will take the drug daily and visit the clinic regularly. The goal is to improve qual…
Phase 3 • Sponsor: Aardvark Therapeutics, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Hope for rare hunger disorder: new drug enters final testing phase
Symptom relief Stopped earlyThis phase 3 trial tests whether ARD-101 can reduce the intense, constant hunger (hyperphagia) seen in Prader-Willi syndrome. About 90 participants will take either ARD-101 or a placebo daily for 12 weeks. Caregivers will track changes in hunger-related behaviors using a standard…
Phase 3 • Sponsor: Aardvark Therapeutics, Inc. • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
CBDV study for Prader-Willi syndrome halted early
Symptom relief Stopped earlyThis study tested whether a cannabis-derived compound called CBDV could safely reduce irritability in children and young adults with Prader-Willi syndrome. Only 6 people enrolled before the study was stopped early. The goal was to see if CBDV helped with mood and behavior problem…
Phase 2 • Sponsor: Eric Hollander • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
Brain and eye clues to emotion recognition in autism and psychosis
Knowledge-focused Stopped earlyThis study aimed to understand why people with autism or schizophrenia sometimes struggle to recognize emotions on faces. Researchers used brain wave recordings (EEG) and eye-tracking to see how participants processed facial expressions. The study included people with autism, sch…
Sponsor: Hôpital le Vinatier • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC